Current Assets
Cash & Equivalents
Medtronic Cash & Equivalents decreased by 10.5% to $1.15B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.5%, from $1.24B to $1.15B. Over 4 years (FY 2021 to FY 2025), Cash & Equivalents shows a downward trend with a -11.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ4 2013
Last reportedQ3 2026Feb 24, 2026
How to read this metric
An increase suggests strong liquidity and capacity for investment, while a decrease may indicate heavy capital expenditure or debt repayment.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and highly liquid i...
Peer comparison
Peers in the medical device sector typically maintain moderate cash balances to balance R&D investment with dividend commitments.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.59B | $3B | $2.9B | $3.48B | $3.71B | $2.14B | $4.83B | $4.52B | $1.54B | $1.34B | $1.31B | $1.62B | $1.28B | $1.31B | $1.39B | $1.24B | $2.22B | $1.27B | $1.28B | $1.15B |
| QoQ Change | — | -16.4% | -3.5% | +20.0% | +6.8% | -42.4% | +125.6% | -6.4% | -65.9% | -13.2% | -2.1% | +23.8% | -20.9% | +2.1% | +6.3% | -11.0% | +78.9% | -42.6% | +0.7% | -10.5% |
| YoY Change | — | — | — | — | +3.4% | -28.8% | +66.5% | +30.0% | -58.5% | -37.4% | -72.8% | -64.1% | -16.8% | -2.1% | +6.3% | -23.6% | +72.7% | -2.9% | -8.0% | -7.5% |
Range$1.15B – $4.83B
CAGR-21.4%
Avg YoY Growth-9.0%
Median YoY Growth-7.8%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Medtronic's cash & equivalents?
- Medtronic (MDT) reported cash & equivalents of $1.15B in Q4 2025.
- How has Medtronic's cash & equivalents changed year-over-year?
- Medtronic's cash & equivalents decreased by 7.5% year-over-year, from $1.24B to $1.15B.
- What is the long-term trend for Medtronic's cash & equivalents?
- Over 4 years (2021 to 2025), Medtronic's cash & equivalents has grown at a -11.4% compound annual growth rate (CAGR), from $3.59B to $2.22B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets that can be accessed immediately.